Discounted Cash Flow (DCF) Analysis Levered

Meridian Bioscience, Inc. (VIVO)

$33.97

0.00 (0.00%)
Financial Summary
Financial Statements
Quarter Financials
Chart
Financial Ratios
Profile
Historical Data
DCFDCF Levered
All numbers are in Millions, Currency in USD
Stock DCF: 80.86 | 33.97 | undervalue

Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 213.57201.01253.67317.90333.02374.97422.21475.40535.29602.72
Revenue (%)
Operating Cash Flow 34.7835.8347.9866.8782.3674.0983.4293.93105.76119.09
Operating Cash Flow (%)
Capital Expenditure -4.20-3.80-3.30-18.31-8.61-10.13-11.40-12.84-14.46-16.28
Capital Expenditure (%)
Free Cash Flow 30.5832.0344.6848.5573.7563.9672.0281.0991.31102.81

Weighted Average Cost Of Capital

Share price $ 33.97
Beta 0.000
Diluted Shares Outstanding 44.01
Cost of Debt
Tax Rate 21.83
After-tax Cost of Debt 3.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 4.683
Total Debt 30.96
Total Equity 1,495.09
Total Capital 1,526.04
Debt Weighting 2.03
Equity Weighting 97.97
Wacc

Build Up Free Cash Flow

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Projected
2024
Projected
2025
Projected
2026
Projected
2027
Projected
Revenue 213.57201.01253.67317.90333.02374.97422.21475.40535.29602.72
Operating Cash Flow 34.7835.8347.9866.8782.3674.0983.4293.93105.76119.09
Capital Expenditure -4.20-3.80-3.30-18.31-8.61-10.13-11.40-12.84-14.46-16.28
Free Cash Flow 30.5832.0344.6848.5573.7563.9672.0281.0991.31102.81
WACC
PV LFCF 48.6952.3956.3760.6565.26
SUM PV LFCF 355.67

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 4.65
Free cash flow (t + 1) 104.86
Terminal Value 3,957.12
Present Value of Terminal Value 3,152.71

Intrinsic Value

Enterprise Value 3,508.37
Net Debt -50.50
Equity Value 3,558.87
Shares Outstanding 44.01
Equity Value Per Share 80.86